APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urotropin for Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urotropin for Injection Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchUrotropin for Injection Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Urotropin for Injection Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Urotropin for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urotropin for Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Urotropin for Injection Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Urotropin for Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urotropin for Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urotropin for Injection market include Yantai Dongcheng North Pharmaceutical, Teva, Shanghai Tianwei Biopharmaceutical Co., Ltd., Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., Qingdao Kangyuan Pharmaceutical, Ningbo Human Health Pharmaceutical Group, Ningbo Human Health Pharmaceutical, Merck and Maanshan Fengyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urotropin for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urotropin for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urotropin for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urotropin for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Urotropin for Injection Segment by Company

Yantai Dongcheng North Pharmaceutical

Teva

Shanghai Tianwei Biopharmaceutical Co., Ltd.

Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.

Qingdao Kangyuan Pharmaceutical

Ningbo Human Health Pharmaceutical Group

Ningbo Human Health Pharmaceutical

Merck

Maanshan Fengyuan Pharmaceutical

Livzon Group

Ferring GmbH

Livzon

IBSA Group

GenSci

Gedeon Richter

Urotropin for Injection Segment by Type

75 Unit

150 Unit

Urotropin for Injection Segment by Application

Hospital

Clinic

Urotropin for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Urotropin for Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Urotropin for Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urotropin for Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Urotropin for Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urotropin for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urotropin for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urotropin for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urotropin for Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urotropin for Injection industry.

Chapter 3: Detailed analysis of Urotropin for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Urotropin for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Urotropin for Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urotropin for Injection Industry Trends Table 2. Urotropin for Injection Industry Drivers Table 3. Urotropin for Injection Industry Opportunities and Challenges Table 4. Urotropin for Injection Industry Restraints Table 5. Global Urotropin for Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urotropin for Injection Revenue Share by Company (2021-2026) Table 7. Global Urotropin for Injection Sales Volume by Company (k units) & (2021-2026) Table 8. Global Urotropin for Injection Sales Volume Share by Company (2021-2026) Table 9. Global Urotropin for Injection Average Price (US$/unit) of Company (2021-2026) Table 10. Global Urotropin for Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Urotropin for Injection Key Company Manufacturing Base & Headquarters Table 12. Global Urotropin for Injection Company, Product Type & Application Table 13. Global Urotropin for Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Urotropin for Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 75 Unit Table 18. Significant Companies of 150 Unit Table 19. Global Urotropin for Injection Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Urotropin for Injection Sales Volume by Type (2021-2026) & (k units) Table 21. Global Urotropin for Injection Sales Volume by Type (2027-2032) & (k units) Table 22. Global Urotropin for Injection Sales Volume Share by Type (2021-2026) Table 23. Global Urotropin for Injection Sales Volume Share by Type (2027-2032) Table 24. Global Urotropin for Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Urotropin for Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Urotropin for Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Urotropin for Injection Sales Value Share by Type (2021-2026) Table 28. Global Urotropin for Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Urotropin for Injection Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Urotropin for Injection Sales Volume by Application (2021-2026) & (k units) Table 33. Global Urotropin for Injection Sales Volume by Application (2027-2032) & (k units) Table 34. Global Urotropin for Injection Sales Volume Share by Application (2021-2026) Table 35. Global Urotropin for Injection Sales Volume Share by Application (2027-2032) Table 36. Global Urotropin for Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Urotropin for Injection Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Urotropin for Injection Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Urotropin for Injection Sales Value Share by Application (2021-2026) Table 40. Global Urotropin for Injection Sales Value Share by Application (2027-2032) Table 41. Global Urotropin for Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Urotropin for Injection Sales by Region (2021-2026) & (k units) Table 43. Global Urotropin for Injection Sales Market Share by Region (2021-2026) Table 44. Global Urotropin for Injection Sales by Region (2027-2032) & (k units) Table 45. Global Urotropin for Injection Sales Market Share by Region (2027-2032) Table 46. Global Urotropin for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Urotropin for Injection Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Urotropin for Injection Sales Value Share by Region (2021-2026) Table 49. Global Urotropin for Injection Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Urotropin for Injection Sales Value Share by Region (2027-2032) Table 51. Global Urotropin for Injection Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Urotropin for Injection Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Urotropin for Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Urotropin for Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Urotropin for Injection Sales by Country (2021-2026) & (k units) Table 56. Global Urotropin for Injection Sales Market Share by Country (2021-2026) Table 57. Global Urotropin for Injection Sales by Country (2027-2032) & (k units) Table 58. Global Urotropin for Injection Sales Market Share by Country (2027-2032) Table 59. Global Urotropin for Injection Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Urotropin for Injection Sales Value Market Share by Country (2021-2026) Table 61. Global Urotropin for Injection Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Urotropin for Injection Sales Value Market Share by Country (2027-2032) Table 63. Yantai Dongcheng North Pharmaceutical Company Information Table 64. Yantai Dongcheng North Pharmaceutical Business Overview Table 65. Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product Portfolio Table 67. Yantai Dongcheng North Pharmaceutical Recent Development Table 68. Teva Company Information Table 69. Teva Business Overview Table 70. Teva Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Teva Urotropin for Injection Product Portfolio Table 72. Teva Recent Development Table 73. Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information Table 74. Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview Table 75. Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio Table 77. Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Development Table 78. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Company Information Table 79. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Business Overview Table 80. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio Table 82. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Development Table 83. Qingdao Kangyuan Pharmaceutical Company Information Table 84. Qingdao Kangyuan Pharmaceutical Business Overview Table 85. Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product Portfolio Table 87. Qingdao Kangyuan Pharmaceutical Recent Development Table 88. Ningbo Human Health Pharmaceutical Group Company Information Table 89. Ningbo Human Health Pharmaceutical Group Business Overview Table 90. Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product Portfolio Table 92. Ningbo Human Health Pharmaceutical Group Recent Development Table 93. Ningbo Human Health Pharmaceutical Company Information Table 94. Ningbo Human Health Pharmaceutical Business Overview Table 95. Ningbo Human Health Pharmaceutical Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Ningbo Human Health Pharmaceutical Urotropin for Injection Product Portfolio Table 97. Ningbo Human Health Pharmaceutical Recent Development Table 98. Merck Company Information Table 99. Merck Business Overview Table 100. Merck Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Merck Urotropin for Injection Product Portfolio Table 102. Merck Recent Development Table 103. Maanshan Fengyuan Pharmaceutical Company Information Table 104. Maanshan Fengyuan Pharmaceutical Business Overview Table 105. Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product Portfolio Table 107. Maanshan Fengyuan Pharmaceutical Recent Development Table 108. Livzon Group Company Information Table 109. Livzon Group Business Overview Table 110. Livzon Group Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Livzon Group Urotropin for Injection Product Portfolio Table 112. Livzon Group Recent Development Table 113. Ferring GmbH Company Information Table 114. Ferring GmbH Business Overview Table 115. Ferring GmbH Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Ferring GmbH Urotropin for Injection Product Portfolio Table 117. Ferring GmbH Recent Development Table 118. Livzon Company Information Table 119. Livzon Business Overview Table 120. Livzon Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Livzon Urotropin for Injection Product Portfolio Table 122. Livzon Recent Development Table 123. IBSA Group Company Information Table 124. IBSA Group Business Overview Table 125. IBSA Group Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. IBSA Group Urotropin for Injection Product Portfolio Table 127. IBSA Group Recent Development Table 128. GenSci Company Information Table 129. GenSci Business Overview Table 130. GenSci Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. GenSci Urotropin for Injection Product Portfolio Table 132. GenSci Recent Development Table 133. Gedeon Richter Company Information Table 134. Gedeon Richter Business Overview Table 135. Gedeon Richter Urotropin for Injection Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Gedeon Richter Urotropin for Injection Product Portfolio Table 137. Gedeon Richter Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Urotropin for Injection Distributors List Table 141. Urotropin for Injection Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Urotropin for Injection Product Image Figure 2. Global Urotropin for Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urotropin for Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Urotropin for Injection Sales (2021-2032) & (k units) Figure 5. Global Urotropin for Injection Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Urotropin for Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 75 Unit Image Figure 10. 150 Unit Image Figure 11. Global Urotropin for Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Urotropin for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Urotropin for Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Urotropin for Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Urotropin for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Urotropin for Injection Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Urotropin for Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Urotropin for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Urotropin for Injection Sales Volume Share by Application (2021-2032) Figure 22. Global Urotropin for Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Urotropin for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Urotropin for Injection Sales Value Share by Application (2021-2032) Figure 25. Global Urotropin for Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Urotropin for Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Urotropin for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Urotropin for Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Urotropin for Injection Sales Value (2021-2032) & (US$ Million) Figure 30. North America Urotropin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Urotropin for Injection Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Urotropin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Urotropin for Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Urotropin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Urotropin for Injection Sales Value (2021-2032) & (US$ Million) Figure 36. South America Urotropin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Urotropin for Injection Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Urotropin for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Urotropin for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Urotropin for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Urotropin for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Urotropin for Injection Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Urotropin for Injection Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 75 Unit
  • 150 Unit
Applications
  • Hospital
  • Clinic
Companies covered
  • Yantai Dongcheng North Pharmaceutical
  • Teva
  • Shanghai Tianwei Biopharmaceutical Co., Ltd.
  • Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
  • Qingdao Kangyuan Pharmaceutical
  • Ningbo Human Health Pharmaceutical Group
  • Ningbo Human Health Pharmaceutical
  • Merck
  • Maanshan Fengyuan Pharmaceutical
  • Livzon Group
  • Ferring GmbH
  • Livzon
  • IBSA Group
  • GenSci
  • Gedeon Richter

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urotropin for Injection Sales Value (2021-2032)
  4. 1.2.2 Global Urotropin for Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Urotropin for Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Urotropin for Injection Market Dynamics
  1. 2.1 Urotropin for Injection Industry Trends
  2. 2.2 Urotropin for Injection Industry Drivers
  3. 2.3 Urotropin for Injection Industry Opportunities and Challenges
  4. 2.4 Urotropin for Injection Industry Restraints
3 Urotropin for Injection Market by Company
  1. 3.1 Global Urotropin for Injection Company Revenue Ranking in 2025
  2. 3.2 Global Urotropin for Injection Revenue by Company (2021-2026)
  3. 3.3 Global Urotropin for Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Urotropin for Injection Average Price by Company (2021-2026)
  5. 3.5 Global Urotropin for Injection Company Ranking (2024-2026)
  6. 3.6 Global Urotropin for Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Urotropin for Injection Company Product Type and Application
  8. 3.8 Global Urotropin for Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Urotropin for Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Urotropin for Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Urotropin for Injection Market by Type
  1. 4.1 Urotropin for Injection Type Introduction
  2. 4.1.1 75 Unit
  3. 4.1.2 150 Unit
  4. 4.2 Global Urotropin for Injection Sales Volume by Type
  5. 4.2.1 Global Urotropin for Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urotropin for Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Urotropin for Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Urotropin for Injection Sales Value by Type
  9. 4.3.1 Global Urotropin for Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Urotropin for Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Urotropin for Injection Sales Value Share by Type (2021-2032)
5 Urotropin for Injection Market by Application
  1. 5.1 Urotropin for Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Urotropin for Injection Sales Volume by Application
  5. 5.2.1 Global Urotropin for Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Urotropin for Injection Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Urotropin for Injection Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Urotropin for Injection Sales Value by Application
  9. 5.3.1 Global Urotropin for Injection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Urotropin for Injection Sales Value by Application (2021-2032)
  11. 5.3.3 Global Urotropin for Injection Sales Value Share by Application (2021-2032)
6 Urotropin for Injection Regional Sales and Value Analysis
  1. 6.1 Global Urotropin for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urotropin for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Urotropin for Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Urotropin for Injection Sales by Region (2027-2032)
  5. 6.3 Global Urotropin for Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Urotropin for Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Urotropin for Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Urotropin for Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Urotropin for Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Urotropin for Injection Sales Value (2021-2032)
  12. 6.6.2 North America Urotropin for Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Urotropin for Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Urotropin for Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Urotropin for Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Urotropin for Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Urotropin for Injection Sales Value (2021-2032)
  21. 6.9.2 South America Urotropin for Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Urotropin for Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Urotropin for Injection Sales Value Share by Country, 2025 VS 2032
7 Urotropin for Injection Country-level Sales and Value Analysis
  1. 7.1 Global Urotropin for Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urotropin for Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Urotropin for Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Urotropin for Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Urotropin for Injection Sales by Country (2027-2032)
  6. 7.4 Global Urotropin for Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Urotropin for Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Urotropin for Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Urotropin for Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Urotropin for Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Urotropin for Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Urotropin for Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Urotropin for Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Urotropin for Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Urotropin for Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Urotropin for Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Urotropin for Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Urotropin for Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Urotropin for Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Urotropin for Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Urotropin for Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Urotropin for Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Urotropin for Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Urotropin for Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Urotropin for Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Urotropin for Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Urotropin for Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Urotropin for Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Urotropin for Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Urotropin for Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Urotropin for Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Urotropin for Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Urotropin for Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Urotropin for Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Urotropin for Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Urotropin for Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Urotropin for Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Urotropin for Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yantai Dongcheng North Pharmaceutical
  2. 8.1.1 Yantai Dongcheng North Pharmaceutical Company Information
  3. 8.1.2 Yantai Dongcheng North Pharmaceutical Business Overview
  4. 8.1.3 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product Portfolio
  6. 8.1.5 Yantai Dongcheng North Pharmaceutical Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Urotropin for Injection Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Shanghai Tianwei Biopharmaceutical Co., Ltd.
  14. 8.3.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
  18. 8.3.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
  20. 8.4.1 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
  24. 8.4.5 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Qingdao Kangyuan Pharmaceutical
  26. 8.5.1 Qingdao Kangyuan Pharmaceutical Company Information
  27. 8.5.2 Qingdao Kangyuan Pharmaceutical Business Overview
  28. 8.5.3 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product Portfolio
  30. 8.5.5 Qingdao Kangyuan Pharmaceutical Recent Developments
  31. 8.6 Ningbo Human Health Pharmaceutical Group
  32. 8.6.1 Ningbo Human Health Pharmaceutical Group Company Information
  33. 8.6.2 Ningbo Human Health Pharmaceutical Group Business Overview
  34. 8.6.3 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product Portfolio
  36. 8.6.5 Ningbo Human Health Pharmaceutical Group Recent Developments
  37. 8.7 Ningbo Human Health Pharmaceutical
  38. 8.7.1 Ningbo Human Health Pharmaceutical Company Information
  39. 8.7.2 Ningbo Human Health Pharmaceutical Business Overview
  40. 8.7.3 Ningbo Human Health Pharmaceutical Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Ningbo Human Health Pharmaceutical Urotropin for Injection Product Portfolio
  42. 8.7.5 Ningbo Human Health Pharmaceutical Recent Developments
  43. 8.8 Merck
  44. 8.8.1 Merck Company Information
  45. 8.8.2 Merck Business Overview
  46. 8.8.3 Merck Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Merck Urotropin for Injection Product Portfolio
  48. 8.8.5 Merck Recent Developments
  49. 8.9 Maanshan Fengyuan Pharmaceutical
  50. 8.9.1 Maanshan Fengyuan Pharmaceutical Company Information
  51. 8.9.2 Maanshan Fengyuan Pharmaceutical Business Overview
  52. 8.9.3 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product Portfolio
  54. 8.9.5 Maanshan Fengyuan Pharmaceutical Recent Developments
  55. 8.10 Livzon Group
  56. 8.10.1 Livzon Group Company Information
  57. 8.10.2 Livzon Group Business Overview
  58. 8.10.3 Livzon Group Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Livzon Group Urotropin for Injection Product Portfolio
  60. 8.10.5 Livzon Group Recent Developments
  61. 8.11 Ferring GmbH
  62. 8.11.1 Ferring GmbH Company Information
  63. 8.11.2 Ferring GmbH Business Overview
  64. 8.11.3 Ferring GmbH Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ferring GmbH Urotropin for Injection Product Portfolio
  66. 8.11.5 Ferring GmbH Recent Developments
  67. 8.12 Livzon
  68. 8.12.1 Livzon Company Information
  69. 8.12.2 Livzon Business Overview
  70. 8.12.3 Livzon Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Livzon Urotropin for Injection Product Portfolio
  72. 8.12.5 Livzon Recent Developments
  73. 8.13 IBSA Group
  74. 8.13.1 IBSA Group Company Information
  75. 8.13.2 IBSA Group Business Overview
  76. 8.13.3 IBSA Group Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 IBSA Group Urotropin for Injection Product Portfolio
  78. 8.13.5 IBSA Group Recent Developments
  79. 8.14 GenSci
  80. 8.14.1 GenSci Company Information
  81. 8.14.2 GenSci Business Overview
  82. 8.14.3 GenSci Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 GenSci Urotropin for Injection Product Portfolio
  84. 8.14.5 GenSci Recent Developments
  85. 8.15 Gedeon Richter
  86. 8.15.1 Gedeon Richter Company Information
  87. 8.15.2 Gedeon Richter Business Overview
  88. 8.15.3 Gedeon Richter Urotropin for Injection Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Gedeon Richter Urotropin for Injection Product Portfolio
  90. 8.15.5 Gedeon Richter Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urotropin for Injection Value Chain Analysis
  2. 9.1.1 Urotropin for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urotropin for Injection Sales Mode & Process
  6. 9.2 Urotropin for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urotropin for Injection Distributors
  9. 9.2.3 Urotropin for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst